Edition:
United Kingdom

Aptose Biosciences Inc (APTO.OQ)

APTO.OQ on NASDAQ Stock Exchange Capital Market

2.18USD
12 Oct 2018
Change (% chg)

-- (--)
Prev Close
$2.18
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
50,672
52-wk High
$4.55
52-wk Low
$1.30

Latest Key Developments (Source: Significant Developments)

Aptose Biosciences QTRLY Loss Per Share $0.30
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Aptose Biosciences Inc ::APTOSE REPORTS RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2018.APTOSE BIOSCIENCES INC - QTRLY LOSS PER SHARE $0.30.APTOSE BIOSCIENCES INC - INCREASE IN QTRLY NET LOSS WAS PRIMARILY DRIVEN BY PAYMENT OF ONE-TIME LICENSE FEES IN AMOUNT $5.0 MILLION TO CRYSTALGENOMICS.APTOSE BIOSCIENCES - EXCLUDING ONE-TIME LICENSE FEES PAYMENTS, NET LOSS FOR THREE MONTHS ENDED JUNE 30, 2018 WOULD HAVE BEEN $5.3 MILLION AND $0.16/SHARE.  Full Article

Aptose Biosciences Says FDA Lifts Clinical Hold So Myc Inhibitor Apto-253 Can Return To Phase 1b Trial
Friday, 29 Jun 2018 

June 29 (Reuters) - Aptose Biosciences Inc ::FDA LIFTS CLINICAL HOLD SO MYC INHIBITOR APTO-253 CAN RETURN TO PHASE 1B TRIAL IN PATIENTS WITH HEMATOLOGIC CANCERS.APTOSE BIOSCIENCES INC - UP TO FIFTEEN CLINICAL CENTERS ARE EXPECTED TO PARTICIPATE IN PHASE 1B TRIAL.  Full Article

Aptose Enters $20 Million Common Share Purchase Agreement With Aspire Capital Fund
Thursday, 31 May 2018 

May 31 (Reuters) - Aptose Biosciences Inc ::APTOSE ENTERS INTO US$20 MILLION COMMON SHARE PURCHASE AGREEMENT WITH ASPIRE CAPITAL FUND, LLC.APTOSE BIOSCIENCES INC - APTOSE WILL CONTROL TIMING AND AMOUNT OF SALE OF COMMON SHARES OF APTOSE TO ASPIRE CAPITAL.APTOSE BIOSCIENCES - ASPIRE CAPITAL TO NOT BE ALLOWED TO BUY MORE THAN 9.9% OF ISSUED, OUTSTANDING COMMON SHARES OF CO WITHOUT PRIOR APPROVAL FROM TSX.APTOSE BIOSCIENCES - AS CONSIDERATION ASPIRE CAPITAL'S OBLIGATION PER AGREEMENT, APTOSE TO ISSUE 170,261 SHARES TO ASPIRE CAPITAL AS COMMITMENT FEE.  Full Article

Aptose Biosciences Says Exercises Early Option For Cg-806 License From Crystalgenomics
Monday, 7 May 2018 

May 7 (Reuters) - Crystal Genomics Inc <083790.KQ>::APTOSE BIOSCIENCES INC - EXERCISES EARLY OPTION FOR CG-806 LICENSE FROM CRYSTALGENOMICS.APTOSE BIOSCIENCES INC - CO OWNS GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE CG-806 FOR ALL INDICATIONS OUTSIDE OF KOREA AND CHINA - LICENSED TERRITORY.APTOSE BIOSCIENCES- CRYSTALGENOMICS ELIGIBLE FOR REGULATORY AND SALES MILESTONE PAYMENTS, AS WELL AS ROYALTIES ON PRODUCT SALES IN LICENSED TERRITORY.APTOSE BIOSCIENCES INC - OPTION EXERCISE TRIGGERS A PAYMENT OF US $2.0 MILLION TO CRYSTALGENOMICS.  Full Article

FDA Grants Orphan Drug Designation To Aptose Biosciences For CG’806 In Acute Myeloid Leukemia
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Aptose Biosciences Inc ::FDA GRANTS ORPHAN DRUG DESIGNATION TO APTOSE BIOSCIENCES FOR CG’806 IN ACUTE MYELOID LEUKEMIA.  Full Article

Aptose Biosciences Files For Offering Of Up To 6 Mln Of Its Common Shares By The Selling Shareholder
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Aptose Biosciences Inc ::APTOSE BIOSCIENCES INC FILES FOR OFFERING OF UP TO 6.0 MILLION OF CO'S COMMON SHARES BY THE SELLING SHAREHOLDER - SEC FILING‍​.  Full Article

Aptose Biosciences Inc Q3 loss per share C$0.14
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Aptose Biosciences Inc :Aptose reports results for the third quarter ended September 30, 2017.Q3 loss per share C$0.14.Aptose Biosciences Inc - ‍total cash and cash equivalents and investments as of September 30, 2017 were $13.6 million​.  Full Article